Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma

Published:2014-02 Issue:2 Volume:4 Page:e183-e183
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Ansell S M,Hodge L S,Secreto F J,Manske M,Braggio E,Price-Troska T,Ziesmer S,Li Y,Johnson S H,Hart S N,Kocher J-P A,Vasmatzis G,Chanan-Kahn A,Gertz M,Fonseca R,Dogan A,Cerhan J R,Novak A J

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj20144.pdf

Reference32 articles.

1. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012; 109: 3879–3884.

2. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181–185.

3. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298–303.

4. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471: 189–195.

5. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88–92.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunoglobulin class‐switch recombination: Mechanism, regulation, and related diseases;MedComm;2024-08

2. Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk stratification, and clinical problems.;Mediterranean Journal of Hematology and Infectious Diseases;2024-06-29

3. Waldenstrom Macroglobulinemia;Comprehensive Hematology and Stem Cell Research;2024

4. MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients;Arthritis Research & Therapy;2023-09-25

5. MYD88 Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges;Hemato;2023-09-13